Incyte hopes to sneak Zynyz through the back door
In first-line NSCLC the drug beats chemo, and not Keytruda.
ASH 2024 preview – best of the rest
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
ESMO 2024 – combos could be the way forward for CDK2
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
ESMO 2024 – Incyte tries again in anal cancer
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
ESMO 2024 preview – presidential focus
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
